JPMorgan analyst Jessica Fye reinstated coverage of Denali Therapeutics with an Overweight rating and $28 price target. The analyst reinstated ratings, estimates and price targets for the U.S. large cap biotechnology space.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DNLI: